Instil Bio financials
$7.14+1.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $2.2M | $0.00 | $0.00 | $2.8M | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | — | $2.2M | $0.00 | $0.00 | $2.8M | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | 100.0% | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating income | -$5.6M | -$7.0M | — | -$12.8M | -$23.4M | -$30.6M | -$9.0M | -$22.1M | -$14.1M | -$24.0M | -$13.0M | -$66.7M |
| Net income | -$4.3M | -$4.2M | — | -$13.6M | -$21.4M | -$28.2M | -$11.9M | -$23.0M | -$14.9M | -$24.3M | -$12.9M | -$67.4M |
| Net margin | — | — | — | −606.0% | — | — | −428.8% | −1541.9% | — | — | — | — |
| Diluted EPS | $-0.63 | $-0.62 | — | $-2.01 | $-3.24 | $-4.32 | $-1.82 | $-3.54 | $-2.29 | $-3.74 | $-1.99 | $-10.37 |
| EBITDA | -$5.2M | -$6.0M | $12.0K | -$12.8M | -$22.9M | -$14.0M | -$8.0M | -$18.9M | -$12.7M | -$18.7M | -$11.8M | -$19.5M |
| Operating cash flow | -$4.6M | -$1.3M | -$7.1M | -$10.6M | -$14.8M | -$4.2M | -$10.6M | -$20.1M | -$10.6M | -$14.4M | -$10.0M | -$14.5M |
| Free cash flow | -$4.6M | -$1.3M | -$7.1M | -$10.6M | -$14.8M | -$4.2M | -$10.6M | -$20.1M | -$10.6M | -$14.4M | -$10.1M | -$19.6M |
| Diluted shares | 6.8M | 6.8M | 6.8M | 6.8M | 6.6M | 6.5M | 6.5M | 6.5M | 6.5M | 6.5M | 6.5M | 6.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.5M | $5.0M | $6.6M | $5.8M | $7.7M | $15.4M |
| Short-term investments | $64.1M | $69.5M | $69.5M | $73.9M | $84.1M | $88.3M |
| Total debt | $85.2M | $85.0M | $84.8M | $84.6M | $84.4M | $84.2M |
| Total assets | $197.7M | $200.4M | $203.5M | $211.8M | $231.0M | $237.4M |
| Total liabilities | $90.3M | $89.7M | $89.7M | $91.3M | $99.3M | $92.5M |
| Shareholders' equity | $107.4M | $110.7M | $113.9M | $120.4M | $131.7M | $144.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology